The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

Shares of Altimmune ( NASDAQ: ALT) traded sharply higher on Friday after the obesity drug developer generated buyout rumors ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Stopping GLP-1 RA treatment 14 days before total joint arthroplasty can minimize risks for complications, according to study findings.

It seems like no matter what I do, I can’t lose weight. Most of my family members struggle with their weight too. Do our ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

Weight loss drugs like Ozempic deliver more health benefits than expected.